We are delighted to extend an invitation to the 3rd series on Vaccines Research and Development Conference which is going to be held in Amsterdam, Netherlands during May 26-28, 2025, [….]
It is with great pleasure to invite you to attend as a Plenary Speaker at our 2nd International Conference on Vaccine Research and Development which is going to be held [….]
Wistar Institute and South Korea’s GeneOne Partner on Nipah Virus Drugs By Mark TerryMay 12, 2023 The Wistar Institute, based in Philadelphia, teamed up with South Korean biotech company GeneOne [….]
Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax’ recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-DUO, now underway in the UK to evaluate the safety and immunogenicity of a third COVID-19 vaccine dose in participants with impaired immune systems.
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan.
Emergent Biosolutions’ vaccine manufacturing plant in Baltimore has been the subject of many headlines this past year for its’ role in producing several COVID-19 Vaccines. However, the history of this facility goes back more than two decades.
University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate – AdCOVID – that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.
Emergent BioSolutions Inc. (NYSE:EBS) announced two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in 415 healthy adults.
Novavax COVID-19 Vaccine: How Does It Work? In the battle against Covid-19, more than 330 million vaccines have been given out. But a new vaccine candidate is about to enter the arena. [….]
